Oral Topotecan With Toripalimab for Patients With Endometrial Cancer

Prior treatment

• Individuals who are known to be allergic, highly sensitive, or intolerant to the active ingredients or other components of the investigational drug;

Other illness

• Serious or uncontrolled infections that may affect research treatment or evaluation of research results, including but not limited to active hepatitis virus infections, positive human immunodeficiency virus (HIV) antibodies, lung infections, etc;
• Other malignant tumors have appeared within the past 5 years, except for cured cervical carcinoma in situ and non melanoma skin cancer;

Age

• Pregnant and lactating patients, women of childbearing age who refuse to take effective contraceptive measures during the study period; Individuals with peripheral nervous system disorders caused by diseases or those with a history of significant mental and central nervous system disorders;

Other

• Patients who are currently participating or have participated in other clinical trials within the past month;
• The researchers determined that the patients were not suitable to participate in this study.

• Age ≥ 18 years old, female;
• Patients with advanced/recurrent endometrial cancer diagnosed by histopathology and failed first-line treatment;
• Can provide 10 pathological white films for subsequent research;
• Physical fitness status score ECOG ≤ 2;
• Expected survival period ≥ 3 months;
• The subjects can understand the research process, voluntarily participate in this study, sign informed consent forms, have good compliance, and cooperate with follow-up.